Mucins and cytokeratins as serum tumor markers in breast cancer

17Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Structural and functional characteristics of mucins and cytokeratins are shortly described. Thereafter, those commonly used in breast cancer as serum tumor markers are considered. First CA15.3, MCA, CA549, CA27.29 mucins and CYFRA21.1, TPA, TPS cytokeratins alone or in association have been examined in different stages and conditions. Then their usefulness in monitoring disease-free breast cancer patients is evaluated. The central role of the established cut-off and critical change, the “early” treatment of recurrent disease and the potential benefit in survival are other issues that have been highlighted and discussed. The successive sections and subsections deal with the monitoring of advanced disease. In them, the current recommendations and the principal findings on using the above mentioned mucins and cytokeratins have been reported. A computer program for interpreting consecutive measurements of serum tumor markers also has been illustrated. The final part of the chapter is devoted to mucins and cytokeratins as markers of circulating and disseminated tumor cells and their usefulness for prognosis.

Cite

CITATION STYLE

APA

Nicolini, A., Ferrari, P., & Rossi, G. (2015). Mucins and cytokeratins as serum tumor markers in breast cancer. In Advances in Experimental Medicine and Biology (Vol. 867, pp. 197–225). Springer New York LLC. https://doi.org/10.1007/978-94-017-7215-0_13

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free